Literature DB >> 2064958

Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases.

S P Mulligan1, E Matutes, C Dearden, D Catovsky.   

Abstract

We studied the natural history and response to treatment in 50 patients with splenic lymphoma with villous lymphocytes followed for a minimum of 6 months and up to 15 years (median 3.7 years). The disease occurs in the elderly (median 68 years) and affects males more than females (M/F ratio 1.77). The median survival for the group was not reached but 82% were surviving at 3 years and 78% at 5 years. Twelve patients (24%) died, one-third of deaths were disease related (four patients) and one-half were due to cardiovascular disease or another malignancy (six patients). The outcome was worse for males (31% died) than females (11% died). Fourteen patients were not treated and 10 remain alive between 1 and 6 years from diagnosis. The remaining patients were treated by chemotherapy, splenic irradiation or splenectomy. The response to chemotherapy was poor and only eight of 22 (36%) patients treated achieved a good response. Splenic irradiation was employed in seven patients and three benefited from it. Splenectomy seems to be the treatment of choice, with significant improvement seen in 19 of 20 patients with one post-operative death. This response, lasting from 6 months to 7 years (median 4 years), was seen irrespective of whether splenectomy was the initial treatment or used later in management.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2064958     DOI: 10.1111/j.1365-2141.1991.tb04417.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Can large B-cell lymphoma mimic cystic lesions of the spleen?

Authors:  Kazuaki Takabe; Waddah Al-Refaie; Brian Chin; Pauline K Chu; Stephen M Baird; Sarah L Blair
Journal:  Int J Gastrointest Cancer       Date:  2005

2.  Surgical approach of primary splenic lymphoma: report of a case and review of the literature.

Authors:  Ioanna Konstantiadou; Aikaterini Mastoraki; Ioannis S Papanikolaou; George Sakorafas; Michael Safioleas
Journal:  Indian J Hematol Blood Transfus       Date:  2009-11-12       Impact factor: 0.900

Review 3.  Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.

Authors:  Sabarish Ayyappan; Basem M William
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

4.  Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma.

Authors:  T Srikumar; M Markow; B Centeno; S Hoffe; J Tao; H Fernandez; J Strosberg; D Shibata
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

5.  Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas.

Authors:  E D Remstein; C D James; P J Kurtin
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

6.  Primary splenic lymphoma with filiform ultrastructure.

Authors:  U R Suresh; B P Eyden; S S Banerjee; N L Reeve
Journal:  J Clin Pathol       Date:  1993-06       Impact factor: 3.411

7.  Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Maria K Angelopoulou; Sotirios Sachanas; Flora N Kontopidou; Xanthi Yiakoumis; Stella I Kokoris; Evagelia M Dimitriadou; Maria N Dimopoulou; Maria Moschogiannis; Penelope Korkolopoulou; Marie-Christine Kyrtsonis; Marina P Siakantaris; Theodora Papadaki; Panayiotis Tsaftaridis; Eleni Plata; Helen E Papadaki; Theodoros P Vassilakopoulos
Journal:  Oncologist       Date:  2013-01-23

8.  A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.

Authors:  Jennifer R Brown; Jonathan W Friedberg; Yang Feng; Sarah Scofield; Kimberly Phillips; Paola Dal Cin; Robin Joyce; Ronald W Takvorian; David C Fisher; Richard I Fisher; Jane Liesveld; Diana Marquis; Donna Neuberg; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

9.  Splenic lymphoma with circulating villous lymphocytes.

Authors:  F Imbing; D Kumar; S Kumar; G Yuoh; F Gardner
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

Review 10.  Splenic marginal zone lymphoma with and without villous lymphocytes.

Authors:  Estella Matutes
Journal:  Curr Treat Options Oncol       Date:  2007-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.